Journal of Clinical Oncology, Vol 12, 2121-2125, Copyright © 1994 by American Society of Clinical Oncology
Renal tolerance of cisplatin in patients more than 80 years old
A Thyss, L Saudes, J Otto, A Creisson, MH Gaspard, O Dassonville and M Schneider
Centre Antoine-Lacassagne, Nice, France.
PURPOSE: Assessment of cisplatin (CDDP) tolerance in patients more than 80
years old in good general condition who may benefit from CDDP-based
treatment. PATIENTS AND METHODS: Data on 35 patients older than 80 years
who received one to six chemotherapy cycles (median, three cycles; total
number of cycles, 98) including CDDP (60 to 100 mg/m2) were analyzed
retrospectively. Before treatment, all patients had normal renal function
as defined by serum creatinine (SC) levels below 132 mumol/L. Renal
function was evaluated by measurement of SC and creatinine clearance (CC)
before and after each course of chemotherapy. CC was calculated according
to the Cockroft and Gault formula, where CC = (140 - age) x weight kg/0.814
x SC mumol/L. Renal toxicity was evaluated by the difference between
prechemotherapy SC and the maximum SC level observed (delta SC) and by the
difference between prechemotherapy CC and the minimal CC observed after
treatment with CDDP (delta CC). The evolution of SC and CC during repeated
courses of CDDP was analyzed, as were any extrarenal toxicities. RESULTS:
Renal function remained stable in 19 patients (54%) with delta SC less than
18 mumol/L and 18 of 35 patients (51%) with delta CC less than 9 mL/min. A
slight deterioration in renal function was observed in 13 patients (37%)
with delta SC greater than 18 mumol/L and less than 60 mumol/L, and with a
delta CC greater than 11 mL/min and less than 21 mL/min. In three patients
(9%), delta SC was greater than 60 mumol/L (71, 73, 115 mumol/L) and delta
CC was greater than 21 mL/min (25, 26, 36 mL/min). There were no cases of
severe renal insufficiency, clinical ototoxicity, or neurotoxicity > or
= grade 2. Treatment was terminated after one or two courses in three
patients because of grade 2 or 3 hematologic toxicity and in two patients
for grade 3 nausea or vomiting. CONCLUSION: CDDP at moderate doses can
reasonably be administered to patients older than 80 years who may benefit
from antineoplastic chemotherapy.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Fruh, E. Rolland, J.-P. Pignon, L. Seymour, K. Ding, H. Tribodet, T. Winton, T. Le Chevalier, G. V. Scagliotti, J. Y. Douillard, et al.
Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
July 20, 2008;
26(21):
3573 - 3581.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol.,
May 10, 2007;
25(14):
1832 - 1843.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gridelli, M. Aapro, A. Ardizzoni, L. Balducci, F. De Marinis, K. Kelly, T. Le Chevalier, C. Manegold, F. Perrone, R. Rosell, et al.
Treatment of Advanced Non-Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
J. Clin. Oncol.,
May 1, 2005;
23(13):
3125 - 3137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Kemeny, B. L. Peterson, A. B. Kornblith, H. B. Muss, J. Wheeler, E. Levine, N. Bartlett, G. Fleming, and H. J. Cohen
Barriers to Clinical Trial Participation by Older Women With Breast Cancer
J. Clin. Oncol.,
June 15, 2003;
21(12):
2268 - 2275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Seluanov, V. Gorbunova, A. Falcovitz, A. Sigal, M. Milyavsky, I. Zurer, G. Shohat, N. Goldfinger, and V. Rotter
Change of the Death Pathway in Senescent Human Fibroblasts in Response to DNA Damage Is Caused by an Inability To Stabilize p53
Mol. Cell. Biol.,
March 1, 2001;
21(5):
1552 - 1564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Sekine, H. Fukuda, H. Kunitoh, and N. Saijo
Cancer Chemotherapy in the Elderly
Jpn. J. Clin. Oncol.,
August 1, 1998;
28(8):
463 - 473.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|